Caris Life Sciences, a precision medicine and AI-driven biotechnology company, has introduced a new breast cancer–focused molecular signature designed to help predict how certain patients may respond to chemotherapy. The tool has been added to the company’s Molecular Tumor Board Report, a research-use-only (RUO) profiling resource available to clinicians and researchers upon request when ordering the MI Cancer Seek® test.
The newly added signature is designed to evaluate potential response to capecitabine, an oral chemotherapy commonly used in breast cancer treatment. According to Caris, the model analyzes more than 2,000 gene expression and copy number features derived from a patient’s Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing (WTS) data. It is intended for use in patients with HER2-negative breast cancer being considered for first-line chemotherapy.
AI-Enhanced Insights for Personalized Cancer Treatment
The breast cancer signature is part of the company’s “Caris AI Insights” section, which includes a series of artificial intelligence–powered analytical tools. These tools draw on Caris’ clinico-genomic database to support research into therapy response prediction, tumor origin identification, metastasis risk assessment, and individualized treatment strategies.
“Molecular profiling is a vital step in gaining a comprehensive understanding of a patient’s cancer,” said David Spetzler, President of Caris Life Sciences. He noted that the AI-driven insights are designed to provide clinicians and researchers with a detailed molecular view of tumor biology to inform care decisions and scientific study.
Built on Comprehensive Genomic Profiling
The Molecular Tumor Board Report is an extension of MI Cancer Seek, Caris’ tissue-based assay. The test received U.S. Food and Drug Administration approval in November 2024 and is described by the company as the first FDA-approved companion diagnostic to simultaneously incorporate Whole Exome and Whole Transcriptome Sequencing for molecular profiling of solid tumors.
By combining broad genomic sequencing with machine learning, Caris aims to uncover patterns that may not be visible through conventional diagnostic methods, supporting the development of more targeted therapies and clinical research approaches.
Company Focused on AI and Large-Scale Clinico-Genomic Data
Headquartered in Irving, Texas, Caris Life Sciences positions itself at the intersection of next-generation sequencing, artificial intelligence, and high-performance computing. The company has built a large-scale multimodal database integrating molecular and clinical data to study disease mechanisms and support advances in early detection, diagnosis, therapy selection, and drug development.
Caris operates additional offices in Phoenix, New York, Cambridge (Massachusetts), Tokyo, and Basel, Switzerland, and provides services in the United States and international markets through partners.
Research-Use Context and Forward Outlook
The Molecular Tumor Board Report and its AI-derived signatures are currently intended for research use, reflecting ongoing efforts to expand the clinical applications of molecular profiling technologies. As with many biotechnology announcements, the company noted that future developments and performance expectations are subject to risks and uncertainties typical of forward-looking statements.
The addition of the capecitabine-response signature underscores the growing role of AI-assisted analytics in oncology, as researchers seek more precise ways to match treatments to the biological characteristics of individual tumors.
